Actively Recruiting
Phase 1 Evaluation of Safety and Body Processing of Oral ID110521156 in Healthy Adults Aged 19 to 50
Led by IlDong Pharmaceutical Co Ltd · Updated on 2024-12-24
36
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, and how the body processes multiple oral doses of the drug ID110521156 in healthy adults aged 19 to 50 years. This phase 1 clinical trial evaluates both the pharmacokinetics and pharmacodynamics of the drug compared to a placebo. The study is sponsored by IlDong Pharmaceutical Co Ltd and aims to gather basic scientific data about this investigational drug. Participants are divided into three groups cohorts, each with 12 healthy volunteers randomized to receive either ID110521156 capsules or placebo capsules once daily. Each cohort includes 10 participants receiving the drug and 2 receiving placebo. The dosing and monitoring occur sequentially across these cohorts to assess safety and drug processing over up to 47 days. During the study, participants undergo various assessments including monitoring for adverse events, blood tests measuring drug levels at multiple time points, and evaluations of blood sugar, insulin, and hemoglobin A1c levels. The study tracks how the drug is absorbed, distributed, and cleared from the body, with visits and tests conducted throughout the dosing period lasting up to 47 days in total.
CONDITIONS
Brief Title
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects
Research Team
C
Clinical Ops Study Leader
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here